コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ncytial virus 24 hrs after the first dose of nalmefene.
2 s further enhanced when co-administered with nalmefene.
3 eatment with an initial ameliorating dose of nalmefene.
4 melioration of the perception of pruritus on nalmefene.
5 and 24 hr after the administration of either nalmefene (1 mg or 1 microg/kg) or naloxone (2 mg or 2 m
9 l gambling were randomly assigned to receive nalmefene (25 mg/day, 50 mg/day, or 100 mg/day) or place
10 ix hundred and four patients (placebo = 298; nalmefene = 306),>/=18 years of age, with a diagnosis of
16 Oral administration of the opioid antagonist nalmefene alone (up to 20 mg/kg) failed to show a signif
21 ndings suggest that the prolonged effects of nalmefene are related to the slow dissociation of nalmef
23 rugs and that the pharmacokinetic profile of nalmefene can be tuned by varying the length of the alky
24 t Month 6, there was a significant effect of nalmefene compared with placebo in reducing the number o
25 therefore demonstrate that sustained plasma nalmefene concentrations can be achieved in both dog and
26 er was chosen to demonstrate that dog plasma nalmefene concentrations were dose-dependent at 1, 5 and
27 at a dose of 5mg-eq. nalmefene/kg and plasma nalmefene concentrations were measured over a four-week
28 eries of studies, three different lipophilic nalmefene derivatives were evaluated: the palmitate (C16
31 fene are related to the slow dissociation of nalmefene from opioid receptors, which are not reflected
34 ents showed that the 25 mg/day and 50 mg/day nalmefene groups had significantly different scores on t
37 improvement in some consumption outcomes for nalmefene (heavy drinking days per month: WMD, -2.0; 95%
39 as-needed use of the opioid system modulator nalmefene in reducing alcohol consumption in patients wi
40 cy and tolerability of the opioid antagonist nalmefene in the treatment of adults with pathological g
44 oral administration of the opiate antagonist nalmefene is associated with any beneficial effects in p
45 n dogs and in minipigs, at a dose of 5mg-eq. nalmefene/kg and plasma nalmefene concentrations were me
49 livered a fairly constant level of 0.2-0.3ng nalmefene/mL plasma for one month and since there was no
50 taking placebo (n = 289) and patients taking nalmefene (n = 290) were included in the efficacy analys
54 to determine the effect of a single dose of nalmefene on striatal blood oxygen level-dependent (BOLD
55 nic administration of the opioid antagonist, nalmefene, on the binding activity of [11C]SCH23390 and
56 ed either a single injection of 10 (mg/kg of nalmefene or control vehicle solution 1 h prior to the P
57 ere chronically administered 10 mg/kg/day of nalmefene or vehicle for 7 days by an osmotic minipump.
58 an be achieved in both dog and minipig using nalmefene prodrugs and that the pharmacokinetic profile
59 is patient population, a number of potential nalmefene prodrugs were synthesized with the aim of prov
61 This longer blockade of opioid receptors by nalmefene represents an advantage in the clinical manage
63 hat in the presence of the alcohol infusion, nalmefene significantly reduced the BOLD response in the
64 Significantly fewer patients treated with nalmefene than patients given placebo relapsed to heavy
67 were higher than corresponding means during nalmefene therapy in 13 (P = .002) and 12 (P = .013) pat
74 2% of the subjects who received 25 mg/day of nalmefene were rated as "much improved" or "very much im
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。